NaturalVue PROTECT 12 month RCT data – Impact of a unique EDOF lens on myopia progression
Provider: Mivision
Contact: Nikki Byrne, [E] nikki@mivision.com.au, [P] 02 8336 8616
Activity Outline
The patients we see in our clinics often fall outside the criteria for inclusion in randomised clinical trials (RCTs), so how can we be confident that the results of a trial will be just as relevant to these patients? Comparing data from both RCTs and studies in the real world give us confidence to know we are making a fully informed decision about the intervention we choose to manage our myopic children.
Dr Brett O’Connor will present the PROTECT (PROgressive Myopia Treatment Evaluation for NaturalVue Multifocal Contact Lens Trial) 1-year interim RCT data from the from Visioneering Technologies Inc. ongoing multi-national, double-masked, randomised controlled trial (RCT). Dr O’Connor will share the efficacy, visual performance and safety of NaturalVue as a myopia progression intervention.
Dr Emma Gillies will present a comparison of NaturalVue 6-year data published in Clinical Ophthalmology (2022)1 and two other independent studies published in 20232,3 with the RCT data, exploring the consistency in the data in diverse study groups.
Learning Objectives
- Understand the importance of evaluating a myopia management intervention using both RCT and real world data
- Appreciate the impact of NaturalVue as a myopia management intervention from the results of the multi-centre international RCT
- Understand the catenary curve design of the NaturalVue extended depth of focus soft contact lens design and how the unique power profile design slows myopic progression in children
Max CPD hours awarded: 1.25
Session Information
| Name |
|---|
| NaturalVue PROTECT 12 month RCT data – Impact of a unique EDOF lens on myopia progression control |
| Clinical? |
| Yes |
| Interactive? |
| No |
| Therapeutic? |
| No |
| Duration of CPD Session/Module |
| 1 |
| Duration of CPD Session/Module inclusive of Assessment Component |
| 1.25 |